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cation was developed as an alternative to the complete wrap in
order to reduce the prevalence of post-operative symptoms such
as bloating and dysphagia. OBJECTIVE: To systematically
review the effectiveness of two different surgical techniques of
laparoscopic fundoplication (partial versus total) for the treat-
ment of GORD in adults. METHODS: A systematic search of
the literature was carried out. All randomised trials comparing
total versus partial laparoscopic fundoplication were included.
The main outcome measure was the number of patients who
were symptom free at follow-up. Other outcome measures
reviewed included clinical outcomes, PROs and QoL. In addi-
tion any long-term follow-up data were reviewed. RESULTS:
Seven randomised trials identiﬁed met the inclusion criteria for
this review. All trials included compared laparoscopic total 
fundoplication compared to partial fundoplication. Post-trial
follow-up results varied between 3–6 months and a variety of
outcome measures were reported. One study reported 12-month
results. There was no reporting on quality of life, though three
trials reported PROs. Dysphagia was more frequently reported
in patients undergoing total fundoplication compared to partial
warp RR 2.82 [95% CI: 18.4, 4.32]. No signiﬁcant differences
in post-operative bloating was found between the two surgical
techniques. There was no signiﬁcant difference in the number of
patients reporting either “good” or “excellent” outcomes
between techniques RR 0.97 [95% CI: 0.89, 1.05]. CONCLU-
SIONS: Evidence from trials supports the view that both total
and partial fundoplication are clinically effective for treating
GORD. However, long-term efﬁcacy and QoL data are needed
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OBJECTIVES: To assess the cost-effectiveness of esomeprazole
(Nexium) compared to lansoprazole (Zoton FasTab) in the initial
treatment of reﬂux oesophagitis over 12 weeks from the per-
spective of the UK NHS. METHODS: A probabilistic decision
analysis model was constructed using Treeage DATATM 4.0 to
depict the sequential management of patients with unhealed
reﬂux oesophagitis. Treatment pathways were based on a pub-
lished 8-week UK healing model, however the model time
horizon was extended by an additional 4 weeks to ensure the
costs incurred by patients who remained unhealed after 8 weeks
were also included. Beta distributions for the 4 and 8 week
healing rates were calculated from a meta-analysis of the two
available head-to-head studies comparing esomeprazole 40mg (4
weeks - r = 2087, n = 2765; 8 weeks r = 342, n = 678) and lan-
soprazole 30mg (4 weeks - r = 1984, n = 2760; 8 weeks r = 347,
n = 776) in the healing of reﬂux oesophagitis. These studies used
the capsules formulation of lansoprazole. This data have been
used, as the capsule and oro-dispersible formulation are bioe-
quivalent. Triangular distributions were ﬁtted to utility values
reported by a study using the rating scale method in patients with
gastro-oesophageal reﬂux disease. Estimates of resource utilisa-
tion were obtained from a survey of UK-based clinicians, and
were multiplied by national published resource unit costs at
2003/04 prices. RESULTS: The mean cost per QALY gained with
esomeprazole and lansoprazole were £1482 and £1633 respec-
tively. Esomeprazole dominated lansoprazole (i.e. was more
effective and less expensive) in 86.8% of the 10,000 Monte
Carlo simulation patient iterations. Applying a willingness to 
pay threshold of £20,000 per QALY similar to that used by
NICE indicates that esomeprazole is cost-effective in 98.9% of
the 10,000 patient iterations. CONCLUSIONS: Esomeprazole 
is more cost-effective than the oro-dispersible formulation of 
lansoprazole in the initial treatment of reﬂux oesophagitis.
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OBJECTIVE: To determine the economic burden of liver cir-
rhosis, a common outcome of chronic hepatitis B, hepatitis C,
and alcoholic liver disease. METHODS: Hospital inpatient
admission records were analyzed for 1993–2001 in a health
insurance claims database (MarketScan® Database) for 3.5–5.0
million employees enrolled annually. All patients >18 years old
admitted with a primary diagnosis of cirrhosis (ICD-9-CM code
571.2 or 571.5) were included in the analysis. For each patient
identiﬁed, all admissions in a year were included except admis-
sions related to hepatocellular carcinoma, liver transplantation,
and admissions unlikely to be due to cirrhosis based on review
of all primary and secondary diagnoses for each admission. Cost
estimates were adjusted for inﬂation using the medical care com-
ponent of consumer price index and are reported in 2002 US$.
RESULTS: A total of 2073 cirrhosis patients with 4049 inpatient
admissions were identiﬁed during the 9-year period. The average
annual number of admissions per patient was 1.5 (95% conﬁ-
dence interval [CI]: 1.5–1.6); average length of hospital stay was
11.1 days (95% CI: 10.1–12.1), which decreased from 12.1 days
in 1995 to 8.1 days in 2000. The annual cost of inpatient care
per patient also decreased, from $31,244 in 1993 to $19,220 in
2000 for an average of $27,248 (95% CI: $24,247–$30,250);
86% (95% CI: 84%–87%) was for hospitalization and 7%
(95% CI: 6%–8%) for physician costs. CONCLUSIONS:
Annual cost of inpatient care for liver cirrhosis in the United
States is >$27,000 per patient hospitalized, more than twice the
average annual cost for all hospital admissions (~$12,000), and
nearly seven times the per capita annual medical care expenses
(~$4176). With >25,000 annual deaths from cirrhosis, this
causes substantial economic burden to society, and underscores
the need to prevent development of cirrhosis by preventing
hepatitis B, hepatitis C, and alcohol abuse.
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OBJECTIVES: A randomized, placebo-controlled trial demon-
strated sustained virological responses (SVR) exceeding 40% in
adult patients with PNALT/CHC using peginterferon alfa-2a
(40-kD) plus ribavirin (Peg/RBV) (Zeuzem. Hepatology 2003;
208A). We computed prognosis, costs, and cost-effectiveness of
